Britain backs GSK’s gene therapy for ‘bubble boy’ syndrome
October 23, 2017
Source: reuters
819
Gene therapy is designed to deliver a one-off cure for the patient and drugmakers are typically asking a hefty price that is comparable to the combined costs of alternative life-long treatment.
Britain’s National Institute for Health and Care Excellence (NICE) said in draft guidance published on Friday that Strimvelis gene therapy used against adenosine deaminase deficiency, or ADA-SCID, improves overall survival compared with standard stem cell transplant therapy.
The inherited condition disables the immune system and without treatment, children with ADA-SCID need to be kept in isolation to avoid infections – hence it has become known as the “bubble baby” or “bubble boy” syndrome.
“Strimvelis represents an important development in the treatment of ADA-SCID, offering the potential to cure the immune aspects of the condition and avoid some of the disadvantages of current treatments,” NICE said.
“Costing 594,000 euros, the treatment is usually given once only and the effects are thought to be life-long,” it added.
The draft guidance marks the first time NICE has applied its new cost effectiveness limits for treatments for very rare conditions.
By Ddu
Copyright©2024 Ddu. All rights reserved.
Read more on
- Disposable Medical Products that Keep Your Medical Facility Clean and Sterile March 31, 2022
- 10 Triumphant Drug Launches Of The Decade August 26, 2021
- NICE backs selective internal radiation therapy for advanced liver cancer March 3, 2021
- Could epigenome editing prevent developmental disorders? December 13, 2019
- Drugdu.com’s 4 most Popular Veterinary APIs and Veterinary medicine Suppliers September 6, 2018
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
